Epelsiban
CAS: 872599-83-2
Ref. 3D-XJB59983
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar |
Información del producto
- Morpholine, 4-[(2R)-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-[(1S)-1-methylpropyl]-2,5-dioxo-1-piperazinyl](2,6-dimethyl-3-pyridinyl)acetyl]-
- (3R,6R)-3-(2,3-Dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione
- GSK 557296
- 2,5-Piperazinedione, 3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-, (3R,6R)-
Epelsiban is a drug that belongs to the class of oxime derivatives. It is used as a modulator and has been shown to have specific treatment effects in animal studies. Epelsiban is also an enantioselective method which targets the oxytocin receptor and has been shown to have single-dose pharmacokinetics. Epelsiban has been shown to be safe in animals, although it can cause adverse reactions such as drug reactions, nausea, vomiting and diarrhea. Epelsiban may also cause endometrial hyperplasia and uterine cancer in women.
Propiedades químicas
Consulta técnica sobre: 3D-XJB59983 Epelsiban
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
